| Literature DB >> 33826885 |
Ronald Derking1, Joel D Allen2, Christopher A Cottrell3, Kwinten Sliepen1, Gemma E Seabright4, Wen-Hsin Lee3, Yoann Aldon1, Kimmo Rantalainen3, Aleksandar Antanasijevic3, Jeffrey Copps3, Anila Yasmeen5, Albert Cupo5, Victor M Cruz Portillo5, Meliawati Poniman1, Niki Bol1, Patricia van der Woude1, Steven W de Taeye1, Tom L G M van den Kerkhof1, P J Klasse5, Gabriel Ozorowski6, Marit J van Gils1, John P Moore5, Andrew B Ward6, Max Crispin7, Rogier W Sanders8.
Abstract
Artificial glycan holes on recombinant Env-based vaccines occur when a potential N-linked glycosylation site (PNGS) is under-occupied, but not on their viral counterparts. Native-like SOSIP trimers, including clinical candidates, contain such holes in the glycan shield that induce strain-specific neutralizing antibodies (NAbs) or non-NAbs. To eliminate glycan holes and mimic the glycosylation of native BG505 Env, we replace all 12 NxS sequons on BG505 SOSIP with NxT. All PNGS, except N133 and N160, are nearly fully occupied. Occupancy of the N133 site is increased by changing N133 to NxS, whereas occupancy of the N160 site is restored by reverting the nearby N156 sequon to NxS. Hence, PNGS in close proximity, such as in the N133-N137 and N156-N160 pairs, affect each other's occupancy. We further apply this approach to improve the occupancy of several Env strains. Increasing glycan occupancy should reduce off-target immune responses to vaccine antigens.Entities:
Keywords: HIV-1 vaccine research; cryo-EM; glycan occupancy; mass spectrometry
Mesh:
Substances:
Year: 2021 PMID: 33826885 PMCID: PMC8804554 DOI: 10.1016/j.celrep.2021.108933
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423
Figure 1.Several PNGS on BG505 SOSIP.v4.1 trimers are under-occupied
(A) Cryo-EM analysis of WT proteins in complex with the RM20E1 Fab. Complexes were sorted based on the number of Fabs bound; the numbers of particles in each reconstruction are listed, as are the resolutions of the final reconstructions.
(B) Overlay of the Cryo-EM reconstructions of the BG505 SOSIP.664 trimer alone (in blue) and in complex with the RM20E1 Fab (in gray). The density of the N611 glycan (also in blue) on the trimer without RM20E1 is highlighted in red to illustrate clashes with the RM20E1 Fab (in gray). The total number of complexes with different numbers of Fab bound is indicated in the table, as are the protomers with N611 glycan density. From these numbers, the % of protomers that lack the N611 glycan could be calculated (~59%).
(C) Linear representation of the D7324-tagged BG505 SOSIP.v4.1 trimer. The SOSIP changes and the stabilizing E64K and A316W mutations are all highlighted (Sanders et al., 2013; de Taeye et al., 2015). The glycans are also indicated, with the amino acid numbering based on the HXB2 strain. Sites that are predominantly occupied by oligomannose species are colored green and by complex species in magenta, whereas orange indicates that either an oligomannose or a complex glycoform can be present, based on data presented in (D). An asterisk indicates that the PNGS is encoded by an NxS sequon.
(D) NS-EM analysis of WT proteins, showing the 2D class-averages.
E) HILIC-UPLC analysis of WT proteins. Peaks colored green represent glycans that can be cleaved by endoglycosidase H (endoH) and correspond to oligomannose or hybrid-type glycans. The HILIC-UPLC spectra and pie chart show the overall oligomannose glycan (green) and complex/hybrid glycan (magenta) content.
(F) Quantification of site-specific occupancy for all 28 PNGS on WT proteins, derived from LC-ESI MS analyses. Results are the mean of two independent biological replicates of the WT protein. The data displayed represents the relative proportion of occupied (blue) versus unoccupied (red). All the data in (A)–(F) were derived using WT proteins produced in HEK293F cells followed by PGT145-affinity purification. The corresponding data on WT proteins purified by the 2G12/SEC method are in Figure S1.
Figure 2.Glycan occupancy is increased by PNGS sequon engineering
(A) NS-EM analysis of NxT proteins showing the 2D class-averages.
(B) HILIC-UPLC analysis of the NxT protein. The color coding of the spectra and pie chart is the same as in Figure 1E.
(C) Quantification of site-specific occupancy for all 28 PNGS on NxT proteins, derived from LC-ESI MS analyses.
(D) Binding of WT and NxT proteins to two N611-directed non-NAbs, RM20E and RM20E1, isolated from BG505 SOSIP.664 immunized rhesus macaques. The area under the curve (AUC) values derived from ELISA titration curves are plotted. *Indicates a significant difference (p < 0.05) between the WT and NxT proteins, calculated using a Mann-Whitney 2-tailed test.
(E) Binding of WT and NxT proteins to three V2-apex directed bNAbs, PGT145, PGDM1400, and CH01, and also 2G12 for comparison. AUC values derived from derived from ELISA titration curves are plotted.
(F) Binding of bNAbs PGT145 and PGT130 to WT and NxT proteins, assessed by SPR. A summary of the binding kinetics for both bNAbs is in Figure S2E.
(G) The EC50 values derived using WT and NxT proteins were plotted and compared using Spearman’s correlation coefficient. All analyses were performed on NxT proteins produced in HEK293F followed by PGT145 purification. The corresponding data on NxT proteins purified by the 2G12/SEC method are in Figure S2.
Figure 3.Occupancy of gap-1 sites can be increased by reducing the affinity of the first site for OST
(A) NS-EM analysis of NxT T158S proteins, showing the 2D class-averages.
(B) HILIC-UPLC analysis of the NxT T158S protein. The color coding of the spectra and pie chart is the same as in Figure 1E.
(C) Quantification of glycan occupancy using LC-ESI MS of the 28 PNGS on NxT T158S proteins.
(D) Quantification of site-specific occupancy for all 28 PNGS on NxT T135S T158S proteins, derived from LC-ESI MS analyses. Results shown are the mean of two independent biological replicates of the NxT T135S T158S protein. The corresponding data on NxT T135S T158S proteins purified by the 2G12/SEC method are in Figure S6.
(E) NS-EM analysis of NxT T135S T158S proteins, showing the 2D class-averages. (F) Binding of non-NAbs RM20E and RM20E1 to WT, NxT, and NxT T135S T158S proteins, assessed by BLI. The bNAb 2G12 was also tested, for comparison. We also tested the binding of bNAbs VRC01, PGT145, and CH01. The average binding curves from 3 independent duplicates are shown. All analyses were performed on NxT T135S T158S trimers produced in HEK293F cells and affinity purified using PGT145.
Figure 4.Sequential improvement of PNGS occupancy on SOSIP trimers
(A) Occupancy of each PNGS on the sequentially improved SOSIP.v4.1 trimers (WT, NxT, NxT T158S, and NxT T135S T158S) is compared with the same site on the BG505 virus. Glycans are modeled onto each PNGS on a 3D model of the WT protein. Color coding reflects the occupancy of each PNGS: light blue, full occupancy (>95%); yellow, 80%–95% occupancy; orange, 70%–80% occupancy, dark red, 60%–70% occupancy; bright red, <60% occupancy.
(B) The sequential changes in PNGS occupancy at each PNGS are shown by the bars. The data shown are the percentage changes in occupancy caused by the various PNGS sequon changes, compared to the same site on the WT BG505 SOSIP.664 trimer.
Occurrence of NxT and NxS sequons in the BG505 sequence compared to 6,516 unique Env sequences found in the Los Alamos database
| Frequency in natural isolates[ | Glycan occupancy (%) | |||||
|---|---|---|---|---|---|---|
| Glycan | BG505 | Motif | % NxT | % NxS | % no PNGS | |
|
| ||||||
| N88 | NxT | NVT | 98.2 | 0.4 | 1.4 | >95 |
| N133 | NxT | NVT | 15.0 | 3.0 | 82.0 | 75 |
| N137 | NxT | NIT | 20.1 | 3.5 | 76.4 | >95 |
| N156 | NxS | NCS | 8.6 | 87.6 | 3.8 | >95 |
| N160 | NxT | NMT | 88.9 | 2.1 | 9.0 | >95 |
| N190 | NxS | NRS | ND[ | ND[ | ND[ | 80 |
| N190c | NxS | NNS | ND[ | ND[ | ND[ | 75 |
| N197 | NxS | NTS | 1.1 | 96.8 | 2.1 | 90 |
| N234 | NxT | NGT | 74.8 | 5.0 | 20.2 | >95 |
| N262 | NxS | NGS | 0.2 | 98.9 | 0.9 | >95 |
| N276 | NxT | NIT | 76.5 | 18.5 | 5.1 | >95 |
| N295 | NxT | NCT | 58.2 | 1.5 | 40.4 | >95 |
| N301 | NxT | NNT | 93.7 | 0.2 | 6.2 | >95 |
| N332 | NxS | NVS | 3.0 | 68.5 | 28.5 | >95 |
| N339 | NxT | NET | 65.1 | 0.1 | 34.8 | >95 |
| N355 | NxT | NNT | 72.8 | 1.6 | 25.5 | >95 |
| N363 | NxS | NSS | 0.4 | 7.7 | 91.9 | >95 |
| N386 | NxS | NTS | 40.0 | 46.8 | 13.2 | >95 |
| N392 | NxT | NST | 70.0 | 9.2 | 20.8 | >95 |
| N398 | NxS | NTS | 11.0 | 2.9 | 86.1 | >95 |
| N406 | NxT | NST | 2.7 | 0.5 | 96.8 | >95 |
| N411 | NxS | NDS | 44.4 | 1.3 | 54.3 | >95 |
| N448 | NxT | NIT | 87.4 | 0.1 | 12.5 | >95 |
| N463 | NxT | NST | ND[ | ND[ | ND[ | >95 |
| N611 | NxS | NSS | 11.6 | 86.8 | 1.6 | 40 |
| N618 | NxS | NLS | 16.6 | 75.3 | 8.1 | >95 |
| N625 | NxT | NMT | 96.2 | 0.0 | 3.8 | >95 |
| N637 | NxT | NYT | 92.5 | 3.8 | 3.7 | >95 |
The occupancy of each PNGS on the BG505 SOSIP.v4.1 trimer is also recorded.
Indicates the PNGS that have an NxS motif.
Data obtained from 6,516 unique HIV envelope sequences found in the Los Alamos database (https://www.hiv.lanl.gov).
PNGS are located in highly variable regions and the specific sites differ between the natural isolates, making reliable calculations not possible.
Figure 5.PNGS sequon engineering is applicable to Env trimers produced in cells from different species and derived from diverse HIV-1 strains
(A) Change in PNGS occupancy between WT proteins produced in ExpiCHO-S cells upon introduction of NxT T135 T158S. The presented data represents the arithmetic difference between the glycan occupancy of the NxT protein minus the WT glycan occupancy, representing a percentage point change (p.p.). A positive p.p. change represents a higher occupancy of the NxT variant compared to the WT. Sites labeled with an asterisk represent those for which data could not be obtained for either the WT or the NxT variant.
(B–D) For additional Env sequences the data is displayed in an identical manner for (B) AMC009, (C) AMC011, and (D) HxB2. N411 was introduced into HxB2 NxT but is not present in WT and is marked as an asterisk.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
|
| ||
| Antibodies | ||
| VRC01 | This paper | RRID: AB_2491019 |
| 3BNC60 | This paper | RRID: AB_2491038 |
| PG9 | This paper | RRID: AB_2491030 |
| PG16 | This paper | RRID: AB_2491031 |
| PGT145 | This paper | RRID: AB_2491054 |
| PGDM1400 | This paper | N/A |
| CH01 | This paper | RRID: AB_2491055 |
| PGT121 | This paper | RRID: AB_2491041 |
| PGT122 | This paper | RRID: AB_2491042 |
| PGT123 | This paper | RRID: AB_2491043 |
| PGT125 | This paper | RRID: AB_2491044 |
| PGT126 | This paper | RRID: AB_2491045 |
| PGT128 | This paper | RRID: AB_2491047 |
| PGT130 | This paper | RRID: AB_2491048 |
| 2G12 | This paper | RRID: AB_2819235 |
| PGT135 | This paper | RRID: AB_2491050 |
| PGT151 | This paper | N/A |
| 35O22 | This paper | N/A |
| 3BC315 | This paper | N/A |
| HIV-Ig | This paper | N/A |
| Goat Anti-Human IgG (HRP) | SeraCare | Cat# 5220–0277 |
| CA13 (ARP3119) | EU Programme EVA Centralized Facility for AIDS Reagents, NIBSC | N/A |
| Anti-HIV-1 gp120 | Aalto Bio Reagents | Cat# D7324 |
Cell lines | ||
| HEK293F cells | Thermo Fisher Scientific | Cat# R79007 |
| HEK293T cells | American Type Culture Collection | Cat.# 11268 |
| ExpiCHO-S cells | Thermo Fisher Scientific | Cat# A29127 |
|
| ||
| Chemicals, peptides, and recombinant proteins | ||
|
| ||
| FectoCHO CD Expression Media | VWR | Cat# 76234–742 |
| FectoPRO DNA transfection kit | VWR | Cat# 10118–842 |
| FreeStyle 293F media | Thermo Fisher Scientific | Cat# 12338026 |
| Opti-MEM Reduced Serum Medium | Thermo Fisher Scientific | Cat# 31985070 |
| PEI MAX transfection reagent | Polysciences | Cat# 24765–1 |
| Lipofectamine 2000 | Life Technologies | Cat# 11668–019 |
| Dulbecco’s Modified Eagles Medium | Life Technologies | Cat# 41966052 |
| Acetonitrile, 80%, 20% Water with 0.1% Formic Acid, Optima LC/MS | Fisher Scientific | Cat# 15431423 |
| Water with 0.1% Formic Acid (v/v), Optima LC/MS Grade | Fisher Scientific | Cat# LS118–212 |
| Acetonitrile | Fisher Scientific | Cat# 10489553 |
| Trifluoroacetic acid | Fisher Scientific | Cat# 10155347 |
| Procainamide hydrochloride | Abcam | Cat# ab120955 |
| H2O18 | Sigma-Aldrich | Cat# 329878 |
| Dithiothreitol | Sigma-Aldrich | Cat# 43819 |
| lodacetamide | Sigma-Aldrich | Cat# I1149 |
| Ammonium formate buffer | Waters | Cat# 186007081 |
| Sodium cyanoborohydride | Sigma-Aldrich | Cat# 156159 |
| DMSO | Sigma-Aldrich | Cat# D2438 |
| Acetic acid | Fisher Scientific | Cat# 10384970 |
| Peptide-N-glycosidase F | New England Biolabs | Cat# P0705S |
| Endoglycosidase H | New England Biolabs | Cat# P0702S |
| Mass spectrometry grade trypsin | Promega | Cat# V5280 |
| Sequencing grade chymotrypsin | Promega | Cat# V1061 |
| HBS-EP buffer | Cytiva | Cat# BR100188 |
| Sensor Chips, CM5 | Cytiva | Cat# 29149604 |
| Aqueous buffer, 10mM Glycine-HCl pH2.0 | Cytiva | Cat# BR100355 |
| Streptavidin (SA) biosensors | Fortebio | Cat#18–5019 |
| Dpnl | New England Biolabs | Cat# R0176S |
| Penicillin | Sigma-Aldrich | P3032–10MU |
| Streptomycin | VWR | 382-EU-100G |
| GIBCO DPBS | Life Technologies | Cat# 12559069 |
| Glycyl Glycine 99+% | Fisher Scientific | Cat# 10540771 |
| MgSO4 | VWR | Cat# 10034–99-8 |
| TitriPlex III (EDTA) | VWR | Cat# 1.08418.1000 |
| Triton X-100 | Fisher Scientific | Cat# BP151500 |
| Tris | Sigma-Aldrich | Cat# 10708976001 |
| HCl | Biosolve | Cat# 084105 |
| Glycine | VWR | Cat# 4500345965 |
| Magnesium Chloride (MgCl2) | VWR | Cat# 4500348228 |
| Sodium Bicarbonate (NaHCO3) | Life Technologies | Cat# 25080094 |
| Sodium Chloride (NaCl) | Sigma-Aldrich | Cat# S7653–1KG |
| Sodium Acetate (NaAc) | VWR | Cat# 1.06268.1000 |
| Citric Acid Monohydrate | Brunschwig | Cat# 36665.22 |
| 3,3′,5,5′-Tetramethylbenzidine (TMB) | Sigma-Aldrich | Cat# T-2885 |
| H2O2 | Brunschwig | Cat# CP26.1 |
| Sulfuric Acid 95–97% | VWR | Cat# 1.00731.1010 |
| Sodium Dodecyl Sulfate | Sigma | Cat# L5750–1kg |
| Glycerol | Thermo Fisher Scientific | Cat# 15514–011 |
| Methanol | Biosolve | Cat# 13680502 |
| Nonfat Dried Milk Powder | VWR | Cat# A0830.0500 |
| Tween-20 | Antibody chain (santacruz) | Cat# SC-29113 |
| Precision Plus Protein Standard Dual Color | Bio-Rad | Cat# 161–0374 |
| Western Lightning Plus-ECL | PerkinElmer | Cat# NEL103001EA |
| NativePAGE Running Buffer | Thermo Fisher Scientific | Cat# BN2001 |
| NativePAGE Cathode Buffer Additive | Thermo Fisher Scientific | Cat# BN2002 |
| MOPS | Sigma | Cat# M1254–250G |
| Coomassie Brilliant Blue G-250 | Fluka | Cat# 27815 |
| HMW-Native Protein Mixture | Cytiva | Cat# 17–0445-01 |
| Bovine Serum Albumine | Sigma | Cat# A7637–10 g |
Critical commercial assays | ||
| In-Fusion HD cloning plus | Takara | Cat# 638910 |
| QuickChange site-directed mutagenesis kit | Agilent | Cat# 200518 |
| NucleoSpin PCR clean-up kit | Macherey-Nagel | Cat# 740609.50 |
| Bright-Glo Luciferase Assay system | Promega | Cat# E2650 |
Deposited data | ||
| BG505 SOSIPv5.2 in complex with PGT122 and two RM20E1 Fabs | This Study | EMD-22170 |
| BG505 SOSIPv5.2 in complex with PGT122 and three RM20E1 Fabs | This Study | EMD-22171 |
| C3 symmetric BG505 SOSIPv5.2 in complex with PGT122 and three RM20E1 Fabs | This Study | EMD-22172 |
| BG505 SOSIPv5.2 in complex with PGT122 and one RM20E1 Fab | This Study | EMD-22173 |
| BG505 SOSIPv5.2 in complex with PGT122 and no RM20E1 Fabs | This Study | EMD-22178 |
| C3 symmetric BG505 SOSIPv5.2 in complex with PGT122 and no RM20E1 Fabs | This Study | EMD-22179 |
Recombinant DNA | ||
| BG505 SOSIP.v4.1 |
| N/A |
| BG505 SOSIP.v5 |
| N/A |
| VRC01 light and heavy chains |
| N/A |
| 3BNC60 light and heavy chains |
| N/A |
| PG9 light and heavy chains |
| N/A |
| PG16 light and heavy chains |
| N/A |
| PGT145 light and heavy chains |
| N/A |
| PGDM1400 light and heavy chains |
| N/A |
| CH01 light and heavy chains |
| N/A |
| PGT121 light and heavy chains |
| N/A |
| PGT122 light and heavy chains |
| N/A |
| PGT123 light and heavy chains |
| N/A |
| PGT125 light and heavy chains |
| N/A |
| PGT126 light and heavy chains |
| N/A |
| PGT128 light and heavy chains |
| N/A |
| PGT130 light and heavy chains |
| N/A |
| 2G12 light and heavy chains |
| N/A |
| PGT135 light and heavy chains |
| N/A |
| PGT151 light and heavy chains |
| N/A |
| 35O22 light and heavy chains |
| N/A |
| 3BC315 light and heavy chains |
| N/A |
| Polyclonal HIV-Ig | NIH AIDS Reagent Program | N/A |
Software and algorithms | ||
| Empower 3.0 | Waters | N/A |
| Masslynx v4.1 | Waters | N/A |
| Driftscope version 2.8 | Waters | N/A |
| Byos™ (Version 3.9) | Protein Metrics Inc. | N/A |
| GraphPad Prism v8 | GraphPad | N/A |
| XCalibur Version v4.2 | Thermo Fisher | N/A |
| Orbitrap Fusion Tune application v3.1 | Thermo Fisher | N/A |
Other | ||
| Superdex 200 Increase 10/300 SEC column | Cytiva | Cat# 28–9909-44 |
| SDS-PAGE 8% Tris-Glycine gel | Invitrogen | Cat# XP00085BOX |
| SDS-PAGE 4–20% Tris-glycine gel | Invitrogen | Cat# XP04205BOX |
| NuPAGE 4–12% Bis-Tris gel | Invitrogen | Cat# NP0321BOX |
| Econo-Column® Chromatography Columns | Bio-Rad | Cat# 7371512 |
| Glycan BEH Amide column (2.1 mmx 100 mm, 1.7 μM) | Waters | Cat# 186004741 |
| EasySpray PepMap RSLC C18 column (75 μm x 75 cm) | Thermo Fisher Scientific | Cat# ES805 |
| PVDF protein-binding membrane | Millipore | Cat# MAIPS4510 |
| C18 ZipTip | Merck Milipore | Cat# ZTC18S008 |
| Spe-ed Amide 2 cartridges | Applied Separations | Cat# 4821 |
| Vivaspin 500, 3 kDa MWCO, Polyethersulfone | Sigma-Aldrich | Cat# GE28–9322–18 |
| Vivaspin 20, 100.000 MWCO PES | Sartorius | Cat# VS2042 |
| PepMap100 C18 3UM 75UMx2CM Nanoviper | Thermo Scientific | 164946 |
| Steritop-GP Filter Unit 0.22μm | Millipore | Cat# SCGPT05RE |
| CNBr-activated Sepharose4B | Cytiva | Cat# 17–0430–01 |
| ELISA-plate, half-area, 96W | Greiner Bio One | Cat# 675061 |
| Hissorb 96-well ELISA plates | QIAGEN | Cat# 35061 |